01.11.2012
- Medical journal The Lancet warned that Sanofi's experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators...
02.05.2012
- Biogen's quarterly profit fell short of analysts' estimates on weak sales of its Avonex multiple sclerosis treatment, its biggest-selling product. But the biotechnology company...
